Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146582 | 0.84 | MAOB (0.43) | MAOBPSMB8PSMB5CA2RIPK1 | |
| SCHEMBL9764869 | 0.75 | MAOB (0.37) | MAOBPSMB8PSMB5CA2MAPT | |
| SCHEMBL14926310 | 0.71 | HDAC1 (0.47) | MAPTRIPK1KDM4EL3MBTL1 | |
| SCHEMBL26247195 | 0.70 | CA2 (0.40) | MAOBDRD2CA2MAPTPTGS2 | |
| SCHEMBL11963733 | 0.70 | PLK1 (0.42) | MAPTRIPK1KDM4E | |
| SCHEMBL2607820 | 0.69 | MAOB (0.40) | MAOBCA2KDM4EPTGS2 | |
| SCHEMBL9764908 | 0.69 | MAOB (0.39) | MAOBCA2MAPTADORA2B | |
| SCHEMBL9764872 | 0.69 | MAOB (0.39) | MAOBDRD2HTR2ADRD3PSMB8 | |
| SCHEMBL9764903 | 0.69 | MAOB (0.42) | MAOBDRD2HTR2ADRD3PSMB8 | |
| SCHEMBL9764896 | 0.68 | MAOB (0.38) | MAOBCA2MAPTADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | MAOB 1595/4885DRD2 2429/4885HTR2A 2938/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885DRD2 2791/4885HTR2A 110/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | MAOB 1595/4885DRD2 2429/4885HTR2A 2938/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885DRD2 2791/4885HTR2A 110/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 1341/4885DRD2 2269/4885HTR2A 429/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | MAOB 1595/4885DRD2 2429/4885HTR2A 2938/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885DRD2 2791/4885HTR2A 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.